Novel biomarkers of atherosclerosis and cardiovascular risk in autoimmune diseases: Genomics and proteomics approaches

Proteomics - Clinical Applications

Volumn 3, Issue 2, 2009, Pages 213-225

  López Pedrera, Chary ^a   Barbarroja, Nuria ^a   Villalba, Jose Manuel ^b  

^a HOSPITAL UNIVERSITARIO REINA SOFÍA   (Spain)

^b UNIVERSITY OF CÓRDOBA   (Spain)

Author keywords

Atherosclerosis; Autoimmune diseases; Cardiovascular disease; Genomics; Proteomics

Indexed keywords

ATORVASTATIN; BETA2 GLYCOPROTEIN 1; BIOLOGICAL MARKER; CD34 ANTIGEN; DISEASE MODIFYING ANTIRHEUMATIC DRUG; FLUINDOSTATIN; GAMMA INTERFERON; HEAT SHOCK PROTEIN 60; HEAT SHOCK PROTEIN 65; HEAT SHOCK PROTEIN 90; HIGH DENSITY LIPOPROTEIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; HYPOXIA INDUCIBLE FACTOR 1ALPHA; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 22; LIPOCORTIN 1; LIPOCORTIN 2; LOW DENSITY LIPOPROTEIN; LUPUS ANTICOAGULANT; MATRIX METALLOPROTEINASE 19; METHOTREXATE; MITOGEN ACTIVATED PROTEIN KINASE KINASE 1; MONOCYTE CHEMOTACTIC PROTEIN 1; OXIDIZED LOW DENSITY LIPOPROTEIN ANTIBODY; PHOSPHOLIPID ANTIBODY; PROSTACYCLIN RECEPTOR; THROMBOPLASTIN; TUMOR NECROSIS FACTOR ALPHA; ZINC FINGER PROTEIN;

ANTIPHOSPHOLIPID SYNDROME; ATHEROSCLEROSIS; AUTOIMMUNE DISEASE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; DISEASE ASSOCIATION; DNA MICROARRAY; DRUG EFFICACY; GENE EXPRESSION; GENE FUNCTION; GENE TARGETING; GENOMICS; HUMAN; IMMUNE RESPONSE; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROGNOSIS; PROTEOMICS; REVIEW; RHEUMATOID ARTHRITIS; RISK FACTOR; SURFACE ENHANCED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; SYSTEMIC LUPUS ERYTHEMATOSUS; UNINDEXED SEQUENCE; VEIN THROMBOSIS;

EID: 65549097347     PISSN: 18628346     EISSN: None     Source Type: Journal    
DOI: 10.1002/prca.200800147     Document Type: Review

References (103)

1. Matsuura, E., Kobayashi, K., Lopez, L. R., Preventing autoimmune and infection triggered atherosclerosis for an enduring healthful lifestyle. Autoimmun. Rev. 2008, 7, 214-222.
2. Bassi, N., Ghirardello, A., Iaccarino, L., Zampieri, S. et al., OxLDL/beta2GPI-anti-oxLDL/beta2GPI complex and atherosclerosis in SLE patients. Autoimmun. Rev. 2007, 7, 52-58.
3. Shoenfeld, Y., Gerli, R., Doria, A., Matsuura, E. et al., Accelerated atherosclerosis in autoimmune rheumatic diseases. Circulation 2005, 112, 3337-3347.
4. Xu, Q., Schett, G., Perschinka, H., Mayr, M. et al., Serum soluble heat shock protein 60 is elevated in subjects with atherosclerosis in a general population. Circulation 2000, 102, 14-20.
5. Kobayashi, K., Kishi, M., Atsumi, T., Bertolaccini, M. L. et al., Circulating oxidized LDL forms complexes with beta2-glycoprotein I: Implication as an atherogenic autoantigen. J. Lipid. Res. 2003, 44, 716-726.
6. Shaw, P. X., Hörkkö, S., Tsimikas, S., Chang, M. K. et al., Human-derived anti-oxidized LDL autoantibody blocks uptake of oxidized LDL by macrophages and localizes to atherosclerotic lesions in vivo. Arterioscler. Thromb. Vasc. Biol. 2001, 21, 1333-1339.
7. Su, J., Georgiades, A., Wu, R., Thulin, T. et al., Antibodies of IgM subclass to phosphorylcholine and oxidized LDL are protective factors for atherosclerosis in patients with hypertension. Atherosclerosis 2006, 188, 160-166.
8. Wu, T., Mohan, C., Proteomics on the diagnostic horizon: Lessons from rheumatology. Am. J. Med. Sci. 2007, 333, 16-25.
9. Lequerré, T., Coulouarn, C., Derambure, C., Lefebvre, G. et al., A new tool for rheumatology: Large-scale analysis of gene expression. Joint Bone Spine 2003, 70, 248-256.
10. Espinosa, G., Cervera, R., Font, J., Shoenfeld, Y., Antiphospholipid syndrome: Pathogenic mechanisms. Autoimmun. Rev. 2003, 2, 86-93.
11. Koike, T., Bohgaki, M., Amengual, O., Atsumi, T., Antiphospholipid antibodies. Lessons from the bench. J. Autoimmun. 2007, 28, 129-133.
12. Cuadrado, M. J., Lopez-Pedrera, C., Khamashta, M. A., Camps, M. T. et al., Thrombosis in primary antiphospholipid syndrome: A pivotal role for monocyte tissue factor expression. Arthritis Rheum. 1997, 40, 834-841.
13. Dobado-Berrios, P. M., Lopez-Pedrera, Ch., Velasco, F., Aguirre, M. A. et al., Increased levels of tissue factor mRNA in mononuclear blood cells of patients with primary anti-phospholipid syndrome. Thromb. Haemost. 1999, 82, 1578-1582.
14. Dobado-Berrios, P. M., Lopez-Pedrera, Ch., Velasco, F., Cuadrado, M. J., The role of TF in the antiphospholipid syndrome. Arthritis. Rheum. 2001, 44, 2467-2476.
15. López-Pedrera, Ch., Buendía, P., Cuadrado, M. J., Siendones, E. et al., Antiphospholipid antibodies from antiphospholipid syndrome patients induce monocyte expression through the simultaneous activation of both NFκB/Rel proteins via p38 MAPK pathway, and the MEK1/ERK pathway. Arthritis Rheum. 2006, 54, 301-311.
16. Vega-Ostertag, M., Harris, E. N., Pierangeli, S. S., Intracellular events in platelet activation induced by antiphospholipid antibodies in the presence of low doses of thrombin. Arthritis Rheum. 2004, 50, 2911-2919.
17. Bohgaki, M., Atsumi, T., Yamashita, Y., Yasuda, S. et al., The p38 mitogen-activated protein kinase (MAPK) pathway mediates induction of the tissue factor gene y monocytes stimulated with human monoclonal anti-beta2glycoprotein I antibodies. Int. Immunol. 2004, 16, 1633-1641.
18. Montiel-Manzano, G., Romay-Penabad, Z., Papalardo de Martinez, E., Meillon-García, L. A. et al., In vivo effects of an inhibitor of nuclear factor-kappa B on thrombogenic properties of antiphospholipid antibodies. Ann. N. Y. Acad. Sci. 2007, 1108, 540-553.
19. Dunoyer-Geindre, S., de Moerloose, P., Galve-de Rochemonteix, B., Reber, G. et al., NFkappa B is an essential intermediate in the activation of endothelial cells by anti-beta(2)-glycoprotein 1 antibodies. Thromb. Haemost. 2002, 88, 851-857.
20. Vega-Ostertag, M., Casper, K., Swerlick, R., Ferrara, D. et al., Involvement of p38 MAPK in the upregulation of tissue factor on endothelial cells by antiphospholipid antibodies. Arthritis Rheum. 2005, 52, 1545-1554.
21. Dvorak, H. F., Vascular permeability factor/vascular endothelial growth factor: A critical cytokine in tumor angiogenesis and a potential target for diagnosis and therapy. J. Clin. Oncol. 2002, 20, 4368-4380.
22. Williams, F. M. K., Parmar, K., Hughes, G. R. V., Hunt, B. J., Systemic endothelial cell markers in primary antiphospholipid syndrome. Thromb. Haemost. 2000, 84, 742-746.
23. Cuadrado, M. J., Buendía, P., Velasco, F., Aguirre, M. A. et al., Vascular endothelial growth factor expression in monocytes from patients with primary antiphospholipid syndrome. J. Thromb. Haemost. 2006, 4, 2461-2469.
24. George, J., Harats, D., Gilburd, B., Afek, A. et al., Immunolocalization of β2-glycoprotein I (apolipoprotein H) to human atherosclerotic plaques: Potential implications for lesion progression. Circulation 1999, 99, 2227-2230.
25. Shoenfeld, Y., Sherer, Y., George, J., Harats, D., Autoantibodies associated with atherosclerosis. Ann. Med. 2000, 32, 37-40.
26. Veres, K., Lakos, G., Kerenyi, A. et al., Antiphospholipid antibodies in acute coronary syndrome. Lupus 2004, 13, 423-427.
27. Jara, L. J., Medina, G., Vera-Lastra, O., Systemic antiphospholipid síndrome and atherosclerosis. Clin. Rev. Allergy Immunol. 2007, 32, 172-177.
28. Potti, A., Bild, A., Dressman, H. K., Lewis, D. A. et al., Gene-expression patterns predict phenotypes of immune-mediated thrombosis. Blood 2006, 107, 1301-1396.
29. López-Pedrera, Ch., Cuadrado, M. J., Hernández, V., Buendía, P. et al., Proteomic analysis in monocytes from antiphospholipid syndrome patients: Deregulation of proteins related to the development of thrombosis. Arthritis Rheum. 2008, 58, 2835-2844.
30. Goulding, N. J., Dixey, J., Morand, E. F., Dodds, R. A. et al., Differential distribution of annexins-I, -II, -IV, and -VI in synovium. Ann. Rheum. Dis. 1995, 54, 841-845.
31. Probst-Cousin, S., Kowolik, D., Kuchelmeister, K., Kayser, C. et al., Expression of annexin-1 in multiple sclerosis plaques. Neuropathol Appl. Neurobiol. 2002, 28, 292-300.
32. Falcone, D. J., Borth, W., Faisal Khan, K. M., Hajjar, K. A., Plasminogen-mediated matrix invasion and degradation by macrophages is dependent on surface expression of annexin II. Blood 2001, 97, 777-784.
33. Zhang, J., McCrae, K. R., Annexin A2 mediates endothelial cell activation by antiphospholipid/anti-β2 glycoprotein I antibodies. Blood 2005, 105, 1964-1969.
34. Ahamed, J., Versteeg, H. H., Kerver, M., Chen, V. M. et al., Disulfide isomerization switches TF from coagulation to cell signalling. Proc. Natl. Acad. Sci. USA 2006, 103, 13932-13937.
35. Amir, R. E., Iwai, K., Ciechanover, A., The NEDD8 pathway is essential for SCFβ-TrCP-mediated ubiquitination and processing of the NFkB precursor p105. J. Biol. Chem. 2002, 277, 23253-23259.
36. Rolfe, B. E., Worth, N. F., World, C. J., Campbell, J. H., Campbell, G. R., Rho and vascular disease. Atherosclerosis 2005, 183, 1-16.
37. D'Cruz, D. P., Khamashta, M. A., Hughes, G. R. V., Systemic lupus erythematosus. Lancet 2007, 369, 587-596.
38. Sherer, Y., Shoenfeld, Y., Mechanisms of disease: Atherosclerosis in autoimmune diseases. Nat. Clin. Pract. Rheumatol. 2006, 2, 99-106.
39. Rhew, E. Z., Ramsey-Goldman, R., Premature atherosclerotic disease in systemic lupus erythematosus-role of inflammatory mechanisms. Autoimmun. Rev. 2006, 5, 101-105.
40. Lee, P. Y., Li, Y., Richards, H. B., Chan, F. S. et al., Type I interferon as novel risk factor for endothelial progenitor cell depletion and endothelial dysfunction in SLE. Arthritis Rheum. 2007, 56, 3759-3769.
41. Rajagopalan, S., Somers, E. C., Brook, R. D., Kehrer, C. et al., Endothelial cell apoptosis in systemic lupus erythematosus: A common pathway for abnormal vascular function and thrombosis propensity. Blood 2004, 103, 3677-3683.
42. McMahona, M., Hahna, B. H., Atherosclerosis and systemic lupus erythematosus: Mechanistic basis of the association. Curr. Opin. Immunol. 2007, 19, 633-639.
43. Maas, K., Chan, S., Parker, J., Slater, A. et al., Cutting Edge: Molecular portrait of human autoimmune disease. J. Immunol. 2002, 165, 5-9.
44. Crow, M. K., George, S., Paget, S. A., Ly, N. et al., Expression of an interferon-alpha gene program in SLE. Arthritis. Rheum. 2002, 46, S281.
45. Han, G. M., Chen, S. L., Shen, L., Ye, S. et al., Analysis of gene expression profiles in human systemic lupus erythematosus using oligonucleotide microarray. Genes Immun. 2003, 4, 177-186.
46. Bennett, L., Palucka, A. K., Arce, E., Cantrell, V. et al., Interferon and granulopoiesis signatures in systemic lupus erythematosus blood. J. Exp. Med. 2003, 197, 711-723.
47. Rus, V., Atamas, S. P., Shustova, V., Luzina, I. G. et al., Expression of cytokine-and chemokine-related genes in peripheral blood mononuclear cells from lupus patients by cDNA array. Clin. Immunol. 2002, 102, 283-290.
48. Baechler, E. C., Batliwalla, F. M., Karypis, G., Gaffney, P. M. et al., Interferon-inducible gene expression signature in peripheral blood cells of patients with severe lupus. Proc. Natl. Acad. Sci. USA 2003, 100, 2610-2515.
49. Ishii, T., Onda, H., Tanigawa, A., Ohshima, S. et al., Isolation and expression profiling of genes upregulated in the peripheral blood cells of systemic lupus erythematosus patients. DNA Res. 2005, 12, 429-439.
50. Crow, M. K., Wohlgemuth, J., Microarray analysis of gene expression in lupus. Arthritis Res. Ther. 2003, 5, 279-287.
51. Qing, X., Putterman, C., Gene expression profiling in the study of the pathogenesis of systemic lupus erythematosus. Autoimmun. Rev. 2004, 3, 505-509.
52. Kirou, K. A., Lee, C., George, S., Louca, K. et al., Coordinate overexpression of interferon-α-induced genes in systemic lupus erythematosus. Arthritis Rheum. 2004, 50, 3958-3967.
53. Dai, Y., Huang, Y. S., Tang, M., Lv, T. Y. et al., Microarray analysis of microRNA expression in peripheral blood cells of systemic lupus erythematosus patients. Lupus 2007, 16, 939-946.
54. Pavón, E. J., Muñoz, P., Lario, A., Longobardo, V. et al., Proteomic analysis of plasma from patients with systemic lupus erythematosus: Increased presence of haptoglobin α2 polypeptide chains over the α1 isoforms. Proteomics 2006, 6, S282-S292.
55. Melamed-Frank, M., Lache, O., Enav, E. I., Szafranek, T. et al., Structure-function analysis of the antioxidant properties of haptoglobin. Blood 2001, 98, 3693-3698.
56. Langlois, M. R., Delanghe, J. R., Biological and clinical significance of haptoglobin polymorphism in humans. Clin. Chem. 1996, 42, 1589-1600.
57. Levy, A. P., Levy, J. E., Kalet-Litman, S., Miller-Lotan, R. et al., Haptoglobin genotype is a determinant of iron, lipid peroxidation, and macrophage accumulation in the atherosclerotic plaque. Arterioscler. Thromb. Vasc. Biol. 2007, 27, 134-140.
58. Guetta, J., Strauss, M., Levy, N. S., Fahoum, L., Levy, A. P., Haptoglobin genotype modulates the balance of Th1/Th2 cytokines produced by macrophages exposed to free haemoglobin. Atherosclerosis 2007, 191, 48-53.
59. Shor, M., Boaz, M., Gavish, D., Wainshtein, J. et al., Relation of haptoglobin phenotype to early vascular changes in patients with diabetes mellitus. Am. J. Cardiol. 2007, 100, 1767-1770.
60. Gerli, R., Sherer, Y., Bocci, E. B., Vaudo, G. et al., Precocious atherosclerosis in rheumatoid arthritis: Role of traditional and disease-related cardiovascular risk factors. Ann. N. Y. Acad. Sci. 2007, 1108, 372-381.
61. del Rincón, I., Freeman, G. L., Haas, R. W., O'Leary, D. H. et al., Relative contribution of cardiovascular risk factors and rheumatoid arthritis clinical manifestations to atherothrombosis. Arthritis Rheum. 2005, 52, 3413-3423.
62. Dhawan, S. S., Quyyumi, A. A., Rheumatoid arthritis and cardiovascular disease. Curr. Atheroscler. Rep. 2008, 10, 128-133.
63. null T cells in patients with acute coronary sundrome. Circulation 2004, 109, 1230-1235.
64. Szekanecz, Z., Kerekes, G., Dér, H., Sándor, Z. et al., Accelerated atherosclerosis in rheumatoid arthritis. Ann. N. Y. Acad. Sci. 2007, 1108, 349-358.
65. Batliwalla, F. M., Baechler, E. C., Xiao, X., Balasubramanian, S. et al., Peripheral blood gene expression profiling in rheumatoid arthritis. Genes Immun. 2005, 6, 388-397.
66. Bovin, L. F., Rieneck, K., Workman, C., Nielsen, H. et al., Blood cell gene expression profiling in rheumatoid arthritis: Discriminative genes and effect of rheumatoid factor. Immunol. Lett. 2004, 93, 217-226.
67. Olsen, N., Sokka, T., Seehorn, C. L., Kraft, B. et al., A gene expression signature for recent onset rheumatoid arthritis in peripheral blood mononuclear cells. Ann. Rheum. Dis. 2004, 63, 1387-1392.
68. Edwards, C. J., Feldman, J. L., Beech, J., Shields, K. M. et al., Molecular profile of peripheral blood mononuclear cells from patients with rheumatoid arthritis. Mol. Med. 2007, 13, 40-58.
69. Tedder, T. F., Steeber, D. A., Chen, A., Engel, P., The selectins: Vascular adhesion molecules. FASEB J. 1995, 9, 866-873.
70. Burke, A. P., Kolodgie, F. D., Zieske, A., Fowler, D. R. et al., Morphologic findings of coronary atherosclerotic plaques in diabetics. A postmortem study. Arterioscler. Thromb. Vasc. Biol. 2004, 24, 1266-1271.
71. Tomlinson, M. G., Heath, V. L., Turck, C. W., Watson, S. P., Weiss, A., SHIP family inositol phosphatases interact with and negatively regulate the Tec tyrosine kinase. J. Biol. Chem. 2004, 279, 55089-55096.
72. Aguado, B., Campbell, R. D., Characterization of a human lysophosphatidic acid acyltransferase that is encoded by a gene located in the class III region of the human major histocompatibility complex. J. Biol. Chem. 1998, 273, 4096-4105.
73. West, J., Tompkins, C. K., Balantac, N., Nudelman, E. et al., Cloning and expression of two human lysophosphatidic acid acyltransferase cDNAs that enhance cytokine-induced signalling responses in cells. DNA Cell. Biol. 1997, 16, 691-701.
74. Naishiro, Y., Suzuki, C., Kimura, M., Yamamoto, M. et al., Plasma analysis of rheumatoid arthritis by SELDI. Nihon Rinsho Meneki Gakkai Kaishi 2007, 30, 145-150.
75. Liz, M. A., Gomes, C. M., Saraiva, M. J., Sousa, M. M., ApoA-I cleaved by transthyretin has reduced ability to promote cholesterol efflux and increased amyloidogenicity. J. Lipid Res. 2007, 48, 2385-2395.
76. Bokarewa, M., Abrahamson, M., Levshin, N., Egesten, A. et al., Cystatin C binds serum amyloid A, downregulating its cytokine-generating properties. J. Rheumatol. 2007, 34, 1293-1301.
77. de Seny, D., Fillet, M., Meuwis, M. A., Geurts, P. et al., Discovery of new rheumatoid arthritis biomarkers using the surface-enhanced laser desorption/ionization time-of-flight mass spectrometry ProteinChip approach. Arthritis Rheum. 2005, 52, 3801-3812.
78. Viemann, D., Strey, A., Janning, A., Jurk, K. et al., Myeloid-related proteins 8 and 14 induce a specific inflammatory response in human microvascular endothelial cells. Blood 2005, 105, 2955-2962.
79. Altwegg, L. A., Neidhart, M., Hersberger, M., Müller, S. et al., Myeloid-related protein 8/14 complex is released by monocytes and granulocytes at the site of coronary occlusion: A novel, early, and sensitive marker of acute coronary syndromes. Eur. Heart J. 2007, 28, 941-948.
80. Dotzlaw, H., Schulz, M., Eggert, M., Neeck, G., A pattern of protein expression in peripheral blood mononuclear cells distinguishes rheumatoid arthritis patients from healthy individuals. Biochim. Biophys. Acta 2004, 1696, 121-129.
81. Schulz, M., Dotzlaw, H., Mikkat, S., Eggert, M., Neeck, G., Proteomic analysis of peripheral blood mononuclear cells: Selective protein processing observed in patients with rheumatoid arthritis. J. Proteome Res. 2007, 6, 3752-3759.
82. Koenig, W., Fibrin(ogen) in cardiovascular disease: An update. Thromb. Haemost. 2003, 89, 601-609.
83. Ross, C. J. D., Katzov, H., Carleton, B., Hayden, M. R., Pharmacogenomics and its implications for autoimmune disease. J. Autoimmun. 2007, 28, 122-128.
84. Sadee, W., Dai, Z., Pharmacogenetics/genomics and personalized medicine. Hum. Mol. Genet. 2003, 4, 937-947.
85. Linkins, L. A., Choi, P. T., Douketis, J. D., Clinical impact of bleeding in patients taking oral anticoagulant therapy for venous thromboembolism: A meta-analysis. Ann. Intern. Med. 2003, 139, 893-900.
86. Wadelius, M., Pirmohamed, M., Pharmacogenetics of warfarin: Current status and future challenges. Pharmacogenomics J. 2006, 7, 99-111.
87. Sanderson, S., Emery, J., Higgins, J., CYP2C9 gene variants, drug dose, and bleeding risk in warfarin-treated patients: A HuGEnet systematic review and meta-analysis. Genet. Med. 2005, 7, 97-104.
88. Takahashi, H., Wilkinson, G. R., Nutescu, E. A., Morita, T. et al., Different contributions of polymorphisms in VKORC1 and CYP2C9 to intra- and inter-population differences in maintenance dose of warfarin in Japanese, Caucasians and African-Americans. Pharmacogenet. Genomics 2006, 16, 101-110.
89. Undas, A., Brummel-Ziedins, E., Mann, K. G., Statins and blood coagulation. Arterioscler. Thromb. Vasc. Biol. 2005, 25, 1-8.
90. Liao, J. K., Laufs, U., Pleiotropic effects of statins. Annu. Rev. Pharmacol. Toxicol. 2005, 45, 89-118.
91. Chasman, D. I., Posada, D., Subrahmanyan, L., Cook, N. R. et al., Pharmacogenetic study of statin therapy and cholesterol reduction. JAMA 2004, 291, 2821-2827.
92. Siest, G., Marteau, J. B., Maumus, S., Berrahmoune, H. et al., Pharmacogenomics and cardiovascular drugs: Need for integrated biological system with phenotypes and proteomic markers. Eur. J. Pharmacol. 2005, 527, 1-22.
93. Duran, M. C., Martin-Ventura, J. L., Mohammed, S., Barderas, M. G. et al., Atorvastatin modulates the profile of proteins released by human atherosclerotic plaques. Eur. J. Pharmacol. 2007, 562, 119-129.
94. Grobbee, D. E., Bots, M. L., Atherosclerotic disease regression with statins: Studies using vascular markers. Int. J. Cardiol. 2004, 96, 447-459.
95. Cuadrado, M. J., Lopez-Pedrera, Ch., Aguirre, A., Hernández, V. et al., Changes operated in protein pattern of monocytes from patients with antiphospholipid Síndrome treated with statins. Abstract ACR 2007.
96. Anderson, N. G., Anderson, N. L., Twenty years of two-dimensional electrophoresis: Past, present and future. Electrophoresis 1996, 17, 443-453.
97. Ranganathan, P., Pharmacogenomics in rheumatoid arthritis. Methods Mol. Biol. 2008, 448, 413-435.
98. Conen, M. J., Tonnen, E. J., Scheffer, H., Radstake, T. R. et al., Pharmacogenetics on anti-TNF treatment in patients with rheumatoid arthritis. Pharmacogenomics 2007, 8, 761-773.
99. Plenge, R. M., Criswell, L. A., Genetic variants that predict response to anti-tumor necrosis factor therapy in rheumatoid arthritis: Current challenges and future directions. Curr. Opin. Rheumatol. 2008, 20, 145-152.
100. Wessels, J. A., Huizinga, T. W., Guchelaar, H. J., Recent insights in the pharmacological actions of methotrexate in the treatment of rheumatoid arthritis. Rheumatology (Oxford) 2008, 47, 249-255.
101. Frostegard, J., Atherosclerosis in patients with autoimmune disorders. Arterioscler. Thromb. Vasc. Biol. 2005, 25, 1776-1785.
102. Toubi, E., Shoenfeld, Y., The role of CD40-CD154 interactions in autoimmunity and the benefit of disrupting this pathway. Autoimmunity 2004, 37, 457-464.
103. Nicoletti, A., Kaveri, S., Caligiuri, G., Bariety, J., Hansson, G. K., Immunoglobulin treatment reduces atherosclerosis in apo E knockout mice. J. Clin. Invest. 1998, 102, 910-918.